


Listing of Claims:



This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A compound of Formula (1.0.0):



– wherein –

- j is 0 or 1; provided that when j is 0, n must be 2;
- k is 0 or 1;
- m is 0, 1, or 2;
- n is 1 or 2;
- A is



– wherein –

--“*” indicates the point of attachment of Formula (1.1.3) to the remaining portion of Formula (1.0.0);

--R⁷ is a member independently selected from the group consisting of

– the following: –

--(1) -H;

--(2) -(C₁-C₆) alkyl; -(C₂-C₆) alkenyl; or -(C₂-C₆) alkynyl; where said alkyl, alkenyl or alkynyl is substituted by 0 to 3 substituents R¹⁰;

– where –

---R¹⁰ is a member selected from the group consisting of phenyl; pyridyl; -F; -Cl; -CF₃; oxo (=O); -OR¹⁶; -NO₂; -CN; -C(=O)OR¹⁶; -O-C(=O)R¹⁶; -C(=O)NR¹⁶R¹⁷; -O-C(=O)NR¹⁶R¹⁷; -NR¹⁶R¹⁷; -NR¹⁶C(=O)R¹⁷; -NR¹⁶C(=O)OR¹⁷; -NR¹⁶S(=O)₂R¹⁷; and -S(=O)₂NR¹⁶R¹⁷; where said phenyl or pyridyl is substituted by 0 to 3 R¹²;

– where –

----R¹² is -F; -Cl; -CF₃; -CN; -NO₂; -OH; -(C₁-C₃) alkoxy; -(C₁-C₃) alkyl; or -NR¹⁶R¹⁷;

– and –

----R¹⁶ and R¹⁷ are each a member independently selected from the group consisting of -H; -(C₁-C₄) alkyl; -(C₂-C₄) alkenyl; -(C₃-C₆) cycloalkyl; phenyl; benzyl; and pyridyl; wherein said alkyl, alkenyl, cycloalkyl, phenyl, benzyl, or pyridyl is substituted by 0 to 3 substituents selected from the group consisting of -F, -Cl, -CF₃, -CN, and -(C₁-C₃) alkyl;

--(3) -(CH₂)_u-(C₃-C₇) cycloalkyl where u is 0, 1 or 2; and further where said (C₃-C₇) cycloalkyl is substituted by 0 to 3 substituents R¹⁰ where R¹⁰ has the same meaning as defined above;

– and –

--(4) phenyl or benzyl, where said phenyl or benzyl is independently substituted by 0 to 3 substituents R¹⁰ where R¹⁰ has the same meaning as defined above;

-----R¹⁸ is selected from the group consisting of -H; -(C₁-C₄) alkyl; and phenyl;

--R⁹ is a member selected from the group consisting of -H; -(C₁-C₄) alkyl; -(C₃-C₇) cycloalkyl; phenyl; benzyl; pyridyl; -C(=O)OR¹⁸; -C(=O)R¹⁸; -OR¹⁸; -(C₁-C₂) alkyl-OR¹⁸; and -(C₁-C₂) alkyl-C(=O)OR¹⁸; where R¹⁸ has the same meaning as defined above; ~~however, when m is 0, and R⁷ is C₄-alkyl, then R⁹ is not H, and when m is 0, and R⁹ is C₄-alkyl, then R⁷ is not H;~~

-W is -O-; -S(=O)_t-, where t is 0, 1, or 2; or -N(R³)- where R³ has the same meaning as defined below;

-Y is =C(R^{1_a})-, where R^{1_a} has the same meaning as defined below;

— where —

--R^{1_a} is a member selected from the group consisting of -H; -F; -Cl; -CN; -NO₂; -(C₁-C₄) alkyl; -(C₂-C₄) alkynyl; fluorinated-(C₁-C₃) alkyl; fluorinated-(C₁-C₃) alkoxy; -OR¹⁶; and -C(=O)NR^{12_a}R^{12_b};


— where —

---R^{12_a} and R^{12_b} are each independently -H; -CH₃; -CH₂CH₃; -CH₂CH₂CH₃; -CH₂(CH₃)₂; -CH₂CH₂CH₂CH₃; -CH(CH₃)CH₂CH₃; -CH₂CH(CH₃)₂; -C(CH₃)₃; cyclopropyl; cyclobutyl; or cyclopentyl;

-R^A and R^B are each a member independently selected from the group consisting of -H; -F; -CF₃; -(C₁-C₄) alkyl; -(C₃-C₇) cycloalkyl; phenyl; and benzyl; wherein said cycloalkyl, phenyl, and benzyl moieties are each independently substituted with 0 to 3 substituents R¹⁰ where R¹⁰ has the same meaning as defined above;

— or —

-R^A and R^B are taken together, but only in the case where m is 1, to form a spiro moiety of Formula (1.2.0):



(1.2.0)

– where –

--r and s are independently 0 to 4 provided that the sum of r + s is at least 1 but not greater than 5;

– and –

--X^A is -CH₂-, -CHR¹², or -C(R¹²)₂- where each R¹² is selected independently of the other and each has the same meaning as defined above; -NR¹⁵-, where R¹⁵ has the same meaning as defined above; -O-; or -S(=O)_t, where t is 0, 1, or 2; and said spiro moiety is substituted as to any one or more carbon atoms thereof by 0 to 3 substituents R¹⁴, as to a nitrogen atom thereof by 0 or 1 substituent R¹⁵, and as to a sulfur atom thereof by 0 or 2 oxygen atoms;

-R^C and R^D have the same meaning as defined above for R^A and R^B except that one of them must be -H, and they are selected independently of each other and of R^A and R^B;

-R¹ and R² may individually or together appear on any ring or rings comprising a meaning of the moiety B² as defined below, and R¹ and R² are each a member independently selected from the group consisting of -H; -F; -Cl; -CN; -NO₂; -(C₁-C₄) alkyl; -(C₂-C₄) alkynyl; fluorinated-(C₁-C₃) alkyl; -OR¹⁶; and -C(=O)NR¹²_aR¹²_b; where R¹²_a and R¹²_b have the same meanings as defined above;

-R³ is -H; -(C₁-C₃) alkyl; phenyl; benzyl; or -OR¹⁶, where R¹⁶ has the same meaning as defined above;

-R⁴, R⁵ and R⁶ may individually or together appear on any ring or rings comprising a meaning of the moiety B¹ as defined below, and R⁴, R⁵ and R⁶ are each a member independently selected from the group consisting of

– the following: –

-(a) -H; provided that R⁵ and R⁶ are not both -H at the same time; -F; -Cl; -(C₂-C₄) alkynyl; -R¹⁶; -OR¹⁶; -S(=O)_pR¹⁶; -C(=O)R¹⁶; -C(=O)OR¹⁶; -OC(=O)R¹⁶; -CN; -NO₂; -C(=O)NR¹⁶R¹⁷; -OC(=O)NR¹⁶R¹⁷; -NR¹²_aC(=O)NR¹⁶R¹⁷; -NR¹²_aC(=NR¹²)NR¹⁶R¹⁷; -NR¹²_aC(=NCN)NR¹⁶R¹⁷; -NR¹²_aC(=N-NO₂)NR¹⁶R¹⁷; -C(=NR¹²_a)NR¹⁶R¹⁷; -CH₂C(=NR¹²_a)NR¹⁶R¹⁷; -OC(=NR¹²_a)NR¹⁶R¹⁷; -OC(=N-NO₂)NR¹⁶R¹⁷; -NR¹⁶R¹⁷; -CH₂NR¹⁶R¹⁷; -NR¹²_aC(=O)R¹⁶; -NR¹²_aC(=O)OR¹⁶; =NOR¹⁶; -NR¹²_aS(=O)_pR¹⁷; -S(=O)_pNR¹⁶R¹⁷; and -CH₂C(=NR¹²_a)NR¹⁶R¹⁷;

– where –

--p is 0, 1, or 2; and R¹²_a, R¹⁶, and R¹⁷ have the same meanings as defined above;


-(b) -(C₁-C₄) alkyl; and -(C₁-C₄) alkoxy, where R⁴, R⁵, or R⁶ has the meaning of -OR¹⁶ under (A) above and R¹⁶ is defined as -(C₁-C₄) alkyl; wherein said alkyl and alkoxy are each independently substituted with 0 to 3 substituents -F or -Cl; or 0 or 1 substituent (C₁-C₂) alkoxy carbonyl-; (C₁-C₂) alkyl carbonyl-; or (C₁-C₂) alkyl carbonyloxy-;

– and –

-(c) an aryl or heterocyclyl moiety selected from the group consisting of phenyl; benzyl; furanyl; tetrahydrofuranyl; oxetanyl; thienyl; tetrahydrothienyl; pyrrolyl; pyrrolidinyl; oxazolyl; oxazolidinyl; isoxazolyl; isoxazolidinyl; thiazolyl; thiazolidinyl; isothiazolyl; isothiazolidinyl; pyrazolyl; pyrazolidinyl; oxadiazolyl; thiadiazolyl; imidazolyl; imidazolidinyl; pyridinyl; pyrazinyl; pyrimidinyl; pyridazinyl; piperidinyl; piperazinyl; triazolyl; triazinyl; tetrazolyl; pyranal; azetidyl; morpholinyl, parathiazinyl; indolyl; indolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 2-*H*-chromenyl; chromanyl; benzothienyl; 1-*H*-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzthiazolyl; quinolinyl; isoquinolinyl; phthalazinyl; quinazolinyl; quinoxalinyl; and purinyl; wherein said aryl and heterocyclyl moieties are each independently substituted with 0 to 2 substituents R¹⁴ where R¹⁴ has the same meaning as defined above;

– or in the case where B¹ is phenyl –

-(d) R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1) through (1.3.15):



– wherein –

-- R^{20} and R^{21} are each a member independently selected from the group consisting of -H; -F; -Cl; -CH₃; -CH₂F; -CHF₂; -CF₃; -OCH₃; and -OCF₃;

-- R^{23} and R^{24} are each independently -H; -CH₃; -OCH₃; -CH₂CH₃; -OCH₂CH₃; -CH₂CH₂CH₃; -CH₂(CH₃)₂; -CH₂CH₂CH₂CH₃; -CH(CH₃)CH₂CH₃; -CH₂CH(CH₃)₂; -C(CH₃)₃; or absent, in which case the dashed line - - - represents a double bond,

provided that in partial Formula (1.3.11) R^{23} and R^{24} may not both be absent at the same time;

$-B^1$ is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic;

– wherein –

said moiety defining B^1 is substituted on any ring or rings thereof by R^4 , R^5 and R^6 , which have the same meaning as defined above;

$-B^2$ is a moiety comprising a saturated or unsaturated carbon ring system that is 3- to 7-membered monocyclic, or that is 7- to 12-membered, fused or discontinuous, polycyclic;

– wherein –


said moiety defining B^2 is substituted on any ring or rings thereof by R^1 and R^2 , which have the same meaning as defined above;

– or –


a pharmaceutically acceptable salt thereof.

2.-7. (cancelled).


8. (original) A compound according to Claim 1 wherein the moiety B^1 is phenyl and R^5 and R^6 are taken together to form a moiety which is a member selected from the group consisting of partial Formulas (1.3.1), (1.3.11), (1.3.12), and (1.3.15):




(1.3.1)



(1.3.11)
























(1.3.12)




(1.3.15)

9. (previously presented) A compound according to Claim 1 wherein B¹ and the substituents R⁴, R⁵, and R⁶ are selected in such a way that the left-hand terminus of said compound of Formula (1.0.0) is represented by the following partial Formulas





(1.8.24)




(1.8.38)




(1.8.41)




(1.8.42)




(1.8.43)




(1.8.44)




(1.8.45)




(1.8.46)




(1.8.47)




(1.8.49)




(1.8.50)




(1.8.51)




(1.8.52)




(1.8.53)




(1.8.54)




(1.8.55)




(1.8.56)




(1.8.57)




(1.8.61)




(1.8.63)




(1.8.64)




(1.8.65)




(1.8.66)




(1.8.67)




(1.8.68)




(1.8.69)



















(1.8.70)




(1.8.69)




10. (previously presented) A compound according to Claim 1 wherein B² and the substituents R¹ and R² are selected in such a way that this portion of the right-hand terminus of said compound of Formula (1.0.0) is represented by the following partial Formulas







(3.0.30)




(3.0.31)




(3.0.32)




(3.0.33)




(3.0.34)




(3.0.35)




(3.0.36)



(3.0.37)



(3.0.46)



(3.0.47)

11.-12. (cancelled).

13. (previously presented) A compound according to Claim 1 wherein B¹ and B² are independently phenyl; m is 1; n is 1; A is a moiety of partial Formula (1.1.3) where R⁷ is -H, or -CH₃ or phenyl independently substituted by 0 or 1 R¹⁰ where R¹⁰ is pyridyl or phenyl substituted by 0-2 of -F, -Cl, -OCH₃, -CN, -NO₂, or -NR¹⁶R¹⁷ where R¹⁶ and R¹⁷ are -H or -CH₃; or R¹⁰ is -F, -Cl, -CF₃, -CN, -OCH₃, -NO₂, -C(=O)OR¹⁶, NR¹⁶R¹⁷, or -S(=O)₂NR¹⁶R¹⁷ where R¹⁶ and R¹⁷ are -H or -CH₃; R⁹ is -H or -CH₃; W is -O-; Y is =C(R^{1a})-; R^{1a} is -H; or -F; R^A and R^B are independently -H or -CH₃; or R^A and R^B are taken together to form a -(C₃-C₇) cycloalkyl-spiro moiety; one of R^C and R^D is -H and the other is -H or -CH₃; R¹ and R² are -H, -F, or -OCH₃; R³ is -H or -CH₃; and R⁴, R⁵ and R⁶ are -H provided that R⁵ and R⁶ are not both -H at the same time, -F, -Cl, -OCH₃, -CN; -NO₂, or -C(=O)R³ or -C(=O)OR³ where R³ is -CH₃; or R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.1), (1.3.2), (1.3.3), (1.3.11), (1.3.12), or (1.3.15), where for partial Formulas (1.3.11), (1.3.12), and (1.3.15), R²³ and R²⁴ are both absent.

14. (original) A compound according to Claim 13 wherein R⁷ is -H; R⁹ is -H; R^A and R^B are taken together to form a cyclopropyl-spiro or cyclobutyl-spiro moiety; R^C and R^D are both -H; R³ is -H; R⁴ and R⁵ are both -H, and R⁶ is -F; or R⁵ and R⁶ are taken together to form a moiety of partial Formula (1.3.1) or (1.3.11).

15.-16. (cancelled).

17. (currently amended) A compound according to Claim 1 wherein said compound is a member selected from the group consisting of the following:

2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-1-methyl-ethyl)-benzyl]-nicotinamide;

2-(Benzo[1,3]dioxol-5-yloxy)-N-(4-carbamoylmethyl-benzyl)-nicotinamide;

N-(4-Carbamoylmethyl-2-fluoro-benzyl)-2-(4-fluoro-phenoxy)-nicotinamide;

2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-carbamoyl-1-methyl-ethyl)-2-fluoro-benzyl]-nicotinamide;

N-[4-(1-Carbamoyl-1-methyl-ethyl)-2-fluoro-benzyl]-2-(4-fluoro-phenoxy)-nicotinamide;

2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-methyl-1-methylcarbamoyl-ethyl)-benzyl]-nicotinamide;

2-(Benzo[1,3]dioxol-5-yloxy)-N-{4-[1-(cyclopropylmethyl-carbamoyl)-1-methyl-ethyl]-benzyl}-nicotinamide; or

2-(Benzo[1,3]dioxol-5-yloxy)-N-[4-(1-ethylcarbamoyl-1-methyl-ethyl)-benzyl]-nicotinamide.

18.-22. (cancelled).